# Cabergoline

## Dostinex 0.5mg

##### 

| TAH Drug Code      | ODOS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
|:-------------------|:--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | Treatment of hyperprolactinemic disorders, either idiopathic or caused by pituitary adenomas.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| Dosing             | Inhibition of physiological lactation soon after parturition 1 mg as a single dose during the 1st postpartum day. Suppression of established lactation: 0.25 mg Q12H for 2 days. Hyperprolactinemic disorders: Initially 0.5 mg/week in 1 or 2 doses which should be increased gradually by adding 0.5 mg/week at monthly intervals. Therapeutic range: 0.25-2 mg/week.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| Hepatic Impairment | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| Renal Impairment   | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| Contraindications  | Known hypersensitivity to cabergoline, ergot derivatives, or any component of the formulation; uncontrolled hypertension; history of cardiac valvular disorders; history of pulmonary, pericardial, or retroperitoneal fibrotic disorders.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| Adverse Effects    | Headache (26%), dizziness (15% to 17%), Nausea (27% to 29%), Orthostatic hypotension (4%), hypotension (1%), dependent edema (1%), edema (peripheral 1%), palpitation (1%), syncope (1%), Fatigue (5% to 7%), vertigo (1% to 4%), depression (3%), somnolence (2% to 5%), nervousness (1% to 2%), anxiety (1%), insomnia (1%), concentration impaired (1%), malaise (1%), Acne (1%), pruritus (1%), Hot flashes (1% to 3%), breast pain (1% to 2%), dysmenorrhea (1%), Constipation (7% to 10%), abdominal pain (5%), dyspepsia (2% to 5%), vomiting (2% to 4%), xerostomia (2%), diarrhea (2%), flatulence (2%), anorexia (1%), throat irritation (1%), toothache (1%), Weakness (6% to 9%), pain (2%), paresthesia (1% to 2%), arthralgia (1%), Abnormal vision (1%), periorbital edema (1%), Rhinitis (1%), Flu-like syndrome (1%) <1% (Limited to important or life-threatening): Aggression, alopecia, cardiac fibrosis, duodenal ulcer (in PD patients), gastric ulcer (in PD patients), pleural effusion, psychosis, pulmonary fibrosis, valvular regurgitation, valvulopathy. |
| Pregnancy          | Human Data Suggest Low Risk                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| Lactation          | Contraindicated                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |

